title: Cannabinoid system of the lateral septum in the modulation of anxiety-like behaviors in rats.
abstract: BACKGROUND
  A large body of evidence suggests that the cannabinoid CB1 receptor plays a key role in the regulation of emotional behaviors. The present study was designed to evaluate the effects of CB1 agonist and antagonist on anxiety-like behaviors in the lateral septum (LS) region of the rat brain using elevated plus maze test.
  
  
  METHODS
  Rats were anesthetized with ketamine and xylazine and special cannulas were inserted stereotaxically into the LS region. After 1 week of recovery, the effects of intra-LS administration of the CB1 receptor agonist, WIN 55,212-2 and CB1 receptor antagonist, AM251, on %OAT and %OAE were measured. Moreover, the effects of pretreatment with AM251 on the response induced by intra-LS administration of WIN 55,212-2 were also assessed.
  
  
  RESULTS
  Intra-LS administration of WIN 55,212-2 (0.001, 0.005 and 0.5μg/rat) decreased the %OAT and %OAE but not locomotor activity, showing an anxiogenic-like response. Intra-LS injection of different doses of AM251 (0.001, 0.01 and 0.1 µg/rat) did not significantly alter the anxiety-like parameters on the plus-maze test. However, intra-LS injections of AM251 (0.01 µg/rat) significantly reversed WIN 55,212-2-induced anxiogenic-like effects.
  
  
  CONCLUSIONS
  The results suggest that the cannabinoid system of the lateral septum modulates anxiety-like behavior through CB1 receptor.
authors: Department of Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran. a.hajizadeh@umz.ac.ir.
authors: Akbar
authors: A
authors: Hajizadeh Moghaddam
authors: Department of Basic Science, Faculty of Veterinary of Medicine, Shahid Chamran, Ahvaz, Iran.
authors: Rata
authors: R
authors: Bigdellu
authors: Department of Basic Science, Faculty of Veterinary of Medicine, Shahid Chamran, Ahvaz, Iran.
authors: Seyed Reza
authors: SR
authors: Fatemi Tabatabaei
authors: Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
authors: Ali
authors: A
authors: Roohbakhsh
mesh_terms: D000818:Animals; D001007:Anxiety / Q000523:psychology; D001522:Behavior, Animal / Q000187:drug effects; D048588:Benzoxazines / Q000494:pharmacology*; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology*; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology*; D005106:Exploratory Behavior / Q000187:drug effects*; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009281:Naphthalenes / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D020665:Septum of Brain / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors
chemical_list: D048588:Benzoxazines; D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; C103505:AM 251; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone